237 related articles for article (PubMed ID: 6198843)
1. Treatment of cutaneous T-cell lymphomas with TP-5. Evaluation of the clinical effect in 8 patients.
Przybilla B; Burg G; Schmoeckel C; Braun-Falco O
Acta Derm Venereol; 1983; 63(6):524-9. PubMed ID: 6198843
[TBL] [Abstract][Full Text] [Related]
2. Thymopoietin pentapeptide (thymopentin, TP-5) in the treatment of rheumatoid arthritis. A compilation of several short- and longterm clinical studies.
Veys EM; Mielants H; Verbruggen G; Spiro T; Newdeck E; Power D; Goldstein G
J Rheumatol; 1984 Aug; 11(4):462-6. PubMed ID: 6384507
[TBL] [Abstract][Full Text] [Related]
3. Therapy with thymopoietin pentapeptide (TP-5) in 26 patients with primary immunodeficiencies.
Aiuti F; Businco L; Fiorilli M; Galli E; Quinti I; Le Moli S; Seminara R; Goldstein G
Birth Defects Orig Artic Ser; 1983; 19(3):267-72. PubMed ID: 6360238
[No Abstract] [Full Text] [Related]
4. [Chemotherapy of cutaneous T-cell lymphomas with arotinoid].
Mahrle G; Thiele B; Ippen H
Dtsch Med Wochenschr; 1983 Nov; 108(46):1753-7. PubMed ID: 6605844
[TBL] [Abstract][Full Text] [Related]
5. [Diagnosis and therapy of cutaneous T-cell lymphomas].
Le T; Pierard GE; Pierard-Franchimont C; de la Brassinne M; Lapière CM
Dermatologica; 1984; 169(2):60-5. PubMed ID: 6332749
[TBL] [Abstract][Full Text] [Related]
6. Non lymphoblastic T cell lymphomas with prevalent skin involvement different from mycosis fungoides or Sézary's syndrome. A retrospective study of 6 cases in Europe.
Grob JJ; Horchowski N; Tubiana N; Gabriel B; Gastaut JA; Hassoun J; Jouve I; Carcassone Y; Bonerandi JJ
Dermatologica; 1988; 177(2):82-97. PubMed ID: 3262542
[TBL] [Abstract][Full Text] [Related]
7. Effect of synthetic thymic hormone (TP5) in children with T-cell immunodeficiencies.
Levinsky RJ; Davies EG; Goldstein G
Birth Defects Orig Artic Ser; 1983; 19(3):273-6. PubMed ID: 6360239
[No Abstract] [Full Text] [Related]
8. Improvement of natural killer activity and of T cells after thymopoietin pentapeptide therapy in a patient with severe combined immunodeficiency.
Fiorilli M; Sirianni MC; Pandolfi F; Quinti I; Tosti U; Aiuti F; Goldstein G
Clin Exp Immunol; 1981 Aug; 45(2):344-51. PubMed ID: 7032772
[TBL] [Abstract][Full Text] [Related]
9. 13-cis-retinoic acid effective in mycosis fungoides. A report from the Scandinavian Mycosis Fungoides Group.
Thomsen K; Molin L; Volden G; Lange Wantzin G; Hellbe L
Acta Derm Venereol; 1984; 64(6):563-6. PubMed ID: 6084938
[TBL] [Abstract][Full Text] [Related]
10. Isotretinoin and cutaneous helper T-cell lymphoma (mycosis fungoides).
Kessler JF; Jones SE; Levine N; Lynch PJ; Booth AR; Meyskens FL
Arch Dermatol; 1987 Feb; 123(2):201-4. PubMed ID: 2949706
[TBL] [Abstract][Full Text] [Related]
11. Stimulation of cellular function by thymopentin (TP-5) in three AIDS patients.
Mascart-Lemone F; Huygen K; Clumeck N; Brenez D; Bolla K; Duchateau J
Lancet; 1983 Sep; 2(8352):735-6. PubMed ID: 6193382
[No Abstract] [Full Text] [Related]
12. [Diagnosis and treatment of skin T-cell lymphoma undergoing transformation in lymphosarcoma].
Vinogradova IuE; Iliushkina EA; Kaplanskaia IB; Lutsenko IN; Zybunova EE; Kremenetskaia AM; Vorob'ev AI
Ter Arkh; 2009; 81(7):57-61. PubMed ID: 19708575
[TBL] [Abstract][Full Text] [Related]
13. Soluble IL2 receptor serum levels and epidermal cytokines in mycosis fungoides and related disorders.
Zachariae C; Larsen CS; Kaltoft K; Deleuran B; Larsen CG; Thestrup-Pedersen K
Acta Derm Venereol; 1991; 71(6):465-70. PubMed ID: 1685826
[TBL] [Abstract][Full Text] [Related]
14. Applying the new TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome in primary cutaneous marginal zone lymphoma.
Gerami P; Wickless SC; Rosen S; Kuzel TM; Ciurea A; Havey J; Guitart J
J Am Acad Dermatol; 2008 Aug; 59(2):245-54. PubMed ID: 18486274
[TBL] [Abstract][Full Text] [Related]
15. Thymopentin in chronic Trichophyton rubrum infection.
Molin L; Bolla K
Surv Immunol Res; 1985; 4 Suppl 1():135-8. PubMed ID: 3898286
[TBL] [Abstract][Full Text] [Related]
16. Bexarotene treatment of late-stage mycosis fungoides and Sézary syndrome: development of extracutaneous lymphoma in 6 patients.
Bouwhuis SA; Davis MD; el-Azhary RA; McEvoy MT; Gibson LE; Knudsen JM; Kist JM; Pittelkow MR
J Am Acad Dermatol; 2005 Jun; 52(6):991-6. PubMed ID: 15928617
[TBL] [Abstract][Full Text] [Related]
17. Effect of subcutaneous thymopentin treatment in drug addicts with persistent generalized lymphadenopathy.
Barcellini W; Meroni PL; Frasca D; Sguotti C; Borghi MO; Uberti-Foppa C; Buzzetti P; Lazzarin A; Doria G; Moroni M
Clin Exp Immunol; 1987 Mar; 67(3):537-43. PubMed ID: 3301099
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of recurrent herpes simplex with thymopoietin-pentapeptide].
Djawari D; Bolla K; Haneke E
Dtsch Med Wochenschr; 1984 Mar; 109(13):496-8. PubMed ID: 6368167
[TBL] [Abstract][Full Text] [Related]
19. Abrogation of in vitro suppressor cell activity in adult common variable hypogammaglobulinemia after TP5 treatment.
Williams RC; Montano JD; Bankhurst AD
J Lab Clin Med; 1983 Jan; 101(1):152-60. PubMed ID: 6217268
[TBL] [Abstract][Full Text] [Related]
20. [Immunomodulating therapy in chronic polyarthritis with thymopentin. A multicenter placebo-controlled study of 119 patients].
Lemmel EM; Bach GL; Bolten W; Brackertz D; Fahmy Z; Mattern H; Stroehmann I; Wittenborg A
Dtsch Med Wochenschr; 1988 Feb; 113(5):172-6. PubMed ID: 3276492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
